TargED Biopharmaceuticals raises 39 M euro in Series A to bring thrombolytic treatment to patients

Richard C.A. Sainson, PhD, experienced R&D executive and scientific leader with demonstrated track record, appointed Chief...

Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a...

PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target...

Eindhoven, the Netherlands – January 19, 2026 –  Sirius Medical, the leader in surgical marker navigation, proudly announces...

Dutch life sciences VC BioGeneration Ventures led TargED’s €21.5 million Series A extension Proceeds will accelerate clinical...

- TGD001 was well tolerated with no dose-limiting toxicities across all dose cohorts, exhibiting potent thrombolytic activity -...